Sequera-Arquelladas, S.; Hidalgo-Tenorio, C.; López-Cortés, L.; Gutiérrez, A.; Santos, J.; Téllez, F.; Omar, M.; Ferra-Murcia, S.; Fernández, E.; Javier, R.;
et al. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain. Viruses 2024, 16, 259.
https://doi.org/10.3390/v16020259
AMA Style
Sequera-Arquelladas S, Hidalgo-Tenorio C, López-Cortés L, Gutiérrez A, Santos J, Téllez F, Omar M, Ferra-Murcia S, Fernández E, Javier R,
et al. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain. Viruses. 2024; 16(2):259.
https://doi.org/10.3390/v16020259
Chicago/Turabian Style
Sequera-Arquelladas, Sergio, Carmen Hidalgo-Tenorio, Luis López-Cortés, Alicia Gutiérrez, Jesús Santos, Francisco Téllez, Mohamed Omar, Sergio Ferra-Murcia, Elisa Fernández, Rosario Javier,
and et al. 2024. "DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain" Viruses 16, no. 2: 259.
https://doi.org/10.3390/v16020259
APA Style
Sequera-Arquelladas, S., Hidalgo-Tenorio, C., López-Cortés, L., Gutiérrez, A., Santos, J., Téllez, F., Omar, M., Ferra-Murcia, S., Fernández, E., Javier, R., GarcÃa-Vallecillos, C., & Pasquau, J.
(2024). DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain. Viruses, 16(2), 259.
https://doi.org/10.3390/v16020259
